23 juni, ExCel London Centre, Londen

PARIJS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, een hoogtechnologisch bedrijf dat de FibroScan®-portfolio van oplossingen aanbiedt, is verheugd aan te kondigen dat zijn oplossingen zullen worden opgenomen in 22 mondelinge presentaties en 157 posters die het gebruik van de niet -invasieve FibroScan®-tool voor een verscheidenheid aan etiologieën van leveraandoeningen en praktijkomgevingen op EASL International Liver Congress™ 2022, 22-26 juni 2022, Londen, Verenigd Koninkrijk. Echosens-leiders presenteren op 23 juni het symposium ‘FibroScan® Solutions Bringing New Guidelines to Life’, 11:00-12:30 uur, Meeting Room N19, ExCel London Centre. Daarnaast biedt Echosens “Hoe vroege screening en behandeling van chronische leverziekte buiten de ziekenhuisomgeving te verbeteren?”– twee demonstraties van FibroScan® GO, 15.00-16.00 uur of 17:30-18:30 uur op 23 juni in Meeting Room N19, ExCel London.

Echosens Presents Symposium & Democenter at EASL International Liver Congress™ 2022: FibroScan® Solutions Bringing New Guidelines to Life, New FibroScan GO Demonstrations

June 23, ExCel London Center, London

PARIS & WALTHAM, Mass.–(BUSINESS WIRE)– Echosens, a high-technology company offering the FibroScan^® portfolio of solutions, is pleased to announce its solutions will be included in 22 oral presentations and 157 posters that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings at EASL International Liver Congress™ 2022, June 22-26, 2022, London, United Kingdom. Echosens leaders will present the symposium “FibroScan^® Solutions Bringing New Guidelines to Life,” 11 a.m.-12:30 p.m., Meeting Room N19, ExCel London Center, on June 23. Additionally, Echosens will offer “How to Improve Early Screening and Management of Chronic Liver Disease Outside Hospital Setting?” — two demonstrations of FibroScan^® GO, 3 p.m.-4 p.m. or 5:30 p.m.-6:30 p.m. on June 23 in Meeting Room N19, ExCel London.

“This very important meeting furthers the worldwide understanding of liver research, enhances the clinical practice of liver disorders and educates those interested in hepatology,” says Dominique Legros, Group CEO, Echosens. “FibroScan^®, the non-invasive solution for comprehensive management of liver health, is recognized worldwide, validated by over 3,500 peer reviewed publications and 160 international guidelines and considered the most widely studied tool for point of care liver assessment.”

Echosens will be available at booth N°46 to discuss and demonstrate early detection with new FibroScan GO, diagnosing and monitoring with FibroScan Mini+ 430 and FibroScan Compact 530, advanced diagnosis and risk stratification with FibroScan Expert 630 live patient demonstration, and digital demonstrations of myFibroScan and Scores by Echosens.

Jon Gingrich, CEO, Echosens North America, adds, “We are thrilled by the global validation of FibroScan and broad consensus of the need for screening and early intervention to prevent advanced liver disease. FibroScan can more cost-effectively identify individuals who are asymptomatic and undiagnosed for liver damage, as well as provide metrics for monitoring changes in liver fat due to lifestyle modification.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan^®, the non-invasive solution for comprehensive management of liver health. FibroScan^® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan^® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

Contacts

Media:
Brittany Tedesco

CPR Communications

btedesco@cpronline.com
201.641.1911 x 14